879551-01-6

Basic information

• Product Name: (4S,5R)-ethyl 5-((R)-2,2-diMethyl-1,3-dioxolan-4-yl)-4-Methyl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide
• Synonyms: (4S,5R)-ethyl 5-((R)-2,2-diMethyl-1,3-dioxolan-4-yl)-4-Methyl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide
• CAS NO: 879551-01-6
• Molecular Weight: 310.325
• Mol File: 879551-01-6.mol

Chemical Properties

• CAS DataBase Reference: (4S,5R)-ethyl 5-((R)-2,2-diMethyl-1,3-dioxolan-4-yl)-4-Methyl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: (4S,5R)-ethyl 5-((R)-2,2-diMethyl-1,3-dioxolan-4-yl)-4-Methyl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide(879551-01-6)
• EPA Substance Registry System: (4S,5R)-ethyl 5-((R)-2,2-diMethyl-1,3-dioxolan-4-yl)-4-Methyl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide(879551-01-6)

Safety Data

• Hazardous Substances Data: 879551-01-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
(4S,5R)-ethyl 5-((R)-2,2-diMethyl-1,3-dioxolan-4-yl)-4-Methyl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide is used as an active pharmaceutical ingredient for its potential therapeutic properties. (4S,5R)-ethyl 5-((R)-2,2-diMethyl-1,3-dioxolan-4-yl)-4-Methyl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide's unique structure and functional groups may allow it to interact with biological targets in ways that could lead to the development of new drugs.
Used in Agrochemical Applications:
In the agrochemical industry, (4S,5R)-ethyl 5-((R)-2,2-diMethyl-1,3-dioxolan-4-yl)-4-Methyl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide is used as a key intermediate in the synthesis of novel pesticides or other agrochemical products. Its specific structural features may provide new modes of action or enhanced efficacy against pests and diseases in agriculture.
Used in Organic Synthesis Processes:
(4S,5R)-ethyl 5-((R)-2,2-diMethyl-1,3-dioxolan-4-yl)-4-Methyl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide is used as a versatile building block in organic synthesis. Its unique structural elements can be employed to construct a variety of complex organic molecules, potentially leading to new materials or compounds with specialized applications in various industries.

Upstream product

• 1020063-91-5 C₁₁H₁₈O₇S 
• 93635-76-8 (2S,3R)-3-[(4R)-2,2-dimethyl-[1,3]dioxolane-4-yl]-2,3-dihydroxy-2-methylpropionic acid ethyl ester 
• 21382-82-1 (carbethoxyethylidene)triphenylphosphorane 
• 15186-48-8 2,3-isopropylidene-glyceraldehyde 
• 130606-67-6 C₁₁H₁₈O₄ 
• 81997-76-4 (S,E)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2-methylpropionic acid ethyl ester 

Downstream Products

• 1496551-72-4 1-((2R,3R,4R,5R)-3-chloro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 1496551-77-9 C₂₂H₂₉ClN₃O₉P 
• 1496551-70-2 2'-deoxy-2'-chloro-2'-C-methyl-3',5'-di-O-benzoyl-N⁴-benzoylcytidine 
• 1613589-83-5 C₆₈H₆₉F₂N₆O₁₀P 
• 1491026-79-9 C₃₃H₂₈NO₉P 

Relevant articles and documents

BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E

The present disclosure is directed toward bi- and monocyclic nucleoside analogs, and compositions comprising these compounds for use in the treatment of hepatitis E infections.

The invention relates to a nano-gold particle catalytic oxidation preparation sulfate method

The invention discloses a method for preparing cyclic sulfate by catalytic oxidation of gold nanoparticles. The method comprises the following steps: dissolving an initial compound, namely (I)-(2S,3R)-3-[(4R)-2,2-dimethyl-1,3-dioxolane]-2,3-diol-2-methyl-ethyl propionate, into a mixed solvent system composed of a non-polar solvent and a polar solvent; adding gold nanoparticles and SOCl2 at 0 DEG C; reacting for 10min at 0 DEG C; then adding an aqueous solution of triethylamine into the reaction system to adjust the pH value to be neutral; naturally heating to room temperature in the presence of an oxidation agent; stirring until the reaction is complete; and separating to obtain the target product. According to the invention, under the action of active oxygen, the conversion rate of vicinal diol is 60-100%; the catalyst shows excellent catalysis performance on the catalytic oxidation reaction of vicinal diol; and the preparation is simple, and the stability is good.

METHOD FOR PRODUCING CYCLIC SULFATE

PROBLEM TO BE SOLVED: To provide an efficient method for producing a cyclic sulfate that is useful as an intermediate for pharmaceuticals and agrochemicals. SOLUTION: The cyclic sulfate can be produced by reacting a starting material, 1,2-diols, with sulfuryl halide in the presence of an inorganic base. Further, it was favorably found that by reacting sulfuryl halide to 1,2-diols under specific conditions, the target material of the present invention, the cyclic sulfate, can be isolated in high selectivity. The present invention enables production of a cyclic sulfate, which has been a little difficult to isolate, in high productivity by one step by a simple work. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Method for preparing intermediate of Sofosbuvir

The invention provides a method for preparing 3,5-bis-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribose-gamma-lactone of D-ribofuranose lactone (structural formula 1). The compound is an important intermediate of a hepatitis C virus (HCV) NS5B polymerase inhibitor Sofosbuvir. The formula 1 is shown in the specification.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

Compounds of Formula (I) are disclosed, wherein R1, R2, R3, R4, R5, and R18 are defined herein. The compounds encompassed by Formula (I) include compounds which are HCV NS5B inhibitors and other compounds which can be metabolized in vivo to HCV NS5B inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

2'-DISUBSTITUTED SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

2'-disubstituted substituted nucleoside derivatives of formula (I) and pharmaceutically acceptable salts thereof are disclosed:(1), wherein A is N3 or NH2 and X, Y, R1, R2, R3, R4,R5 and R18 are as defined herein. Compositions comprising at least one 2'-disubstituted nucleoside derivative, and methods of using the 2'-disubstituted nucleoside derivatives for treating or preventing HCV infection in a patient are disclosed.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to 2′-Cyano Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Cyano Substituted Nucleoside Derivative, and methods of using the 2′-Cyano Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.